secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001193125-23-128726
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Neurosciences announces FDA files NDA for roluperidone after appeal of refuse-to-file
--------------------------------------------------------------------------------

- FDA filed Minerva's NDA for roluperidone on April 27, 2023, to treat negative symptoms in schizophrenia.
- FDA had issued a refuse-to-file letter in October 2022; appeal granted by FDA deciding official.
- Issues from the April 2022 Type C meeting will be considered during NDA review.
- No approved treatments exist for negative symptoms of schizophrenia; roluperidone aims to address that gap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312523128726/0001193125-23-128726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312523128726/d365950d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-128726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer